Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

Treatment with glucokinase activator, YH-GKA, increases cell proliferation and decreases glucotoxic apoptosis in INS-1 cells.

Oh YS, Lee YJ, Park K, Choi HH, Yoo S, Jun HS.

Eur J Pharm Sci. 2014 Jan 23;51:137-45. doi: 10.1016/j.ejps.2013.09.005. Epub 2013 Sep 18.

PMID:
24056026
2.

Effects of glucokinase activators GKA50 and LY2121260 on proliferation and apoptosis in pancreatic INS-1 beta cells.

Wei P, Shi M, Barnum S, Cho H, Carlson T, Fraser JD.

Diabetologia. 2009 Oct;52(10):2142-50. doi: 10.1007/s00125-009-1446-0. Epub 2009 Jul 30.

PMID:
19641898
3.

Embelin-Induced Apoptosis of Human Prostate Cancer Cells Is Mediated through Modulation of Akt and β-Catenin Signaling.

Park N, Baek HS, Chun YJ.

PLoS One. 2015 Aug 7;10(8):e0134760. doi: 10.1371/journal.pone.0134760. eCollection 2015.

5.

Identification of YH-GKA, a novel benzamide glucokinase activator as therapeutic candidate for type 2 diabetes mellitus.

Park K.

Arch Pharm Res. 2012 Dec;35(12):2029-33. doi: 10.1007/s12272-012-1201-9. Review.

PMID:
23263798
6.

Glucokinase activation ameliorates ER stress-induced apoptosis in pancreatic β-cells.

Shirakawa J, Togashi Y, Sakamoto E, Kaji M, Tajima K, Orime K, Inoue H, Kubota N, Kadowaki T, Terauchi Y.

Diabetes. 2013 Oct;62(10):3448-58. doi: 10.2337/db13-0052. Epub 2013 Jun 25.

7.

A novel mechanism of hepatocellular carcinoma cell apoptosis induced by lupeol via Brain-Derived Neurotrophic Factor Inhibition and Glycogen Synthase Kinase 3 beta reactivation.

Zhang L, Tu Y, He W, Peng Y, Qiu Z.

Eur J Pharmacol. 2015 Sep 5;762:55-62. doi: 10.1016/j.ejphar.2015.05.030. Epub 2015 May 21.

PMID:
26004524
8.

Tob1 induces apoptosis and inhibits proliferation, migration and invasion of gastric cancer cells by activating Smad4 and inhibiting β‑catenin signaling.

Kundu J, Wahab SM, Kundu JK, Choi YL, Erkin OC, Lee HS, Park SG, Shin YK.

Int J Oncol. 2012 Sep;41(3):839-48. doi: 10.3892/ijo.2012.1517. Epub 2012 Jun 12.

9.

Compound 19e, a Novel Glucokinase Activator, Protects against Cytokine-Induced Beta-Cell Apoptosis in INS-1 Cells.

Oh YS, Seo E, Park K, Jun HS.

Front Pharmacol. 2017 Mar 29;8:169. doi: 10.3389/fphar.2017.00169. eCollection 2017.

10.

Control of beta cell function and proliferation in mice stimulated by small-molecule glucokinase activator under various conditions.

Nakamura A, Togashi Y, Orime K, Sato K, Shirakawa J, Ohsugi M, Kubota N, Kadowaki T, Terauchi Y.

Diabetologia. 2012 Jun;55(6):1745-54. doi: 10.1007/s00125-012-2521-5. Epub 2012 Mar 29.

PMID:
22456697
11.

Recent updates on glucokinase activators for the treatment of type 2 diabetes mellitus.

Grewal AS, Sekhon BS, Lather V.

Mini Rev Med Chem. 2014;14(7):585-602. Review.

PMID:
25052034
12.

Nitric oxide inhibits the proliferation and invasion of pancreatic cancer cells through degradation of insulin receptor substrate-1 protein.

Sugita H, Kaneki M, Furuhashi S, Hirota M, Takamori H, Baba H.

Mol Cancer Res. 2010 Aug;8(8):1152-63. doi: 10.1158/1541-7786.MCR-09-0472. Epub 2010 Jul 27.

13.

Chronic treatment with a glucokinase activator delays the onset of hyperglycaemia and preserves beta cell mass in the Zucker diabetic fatty rat.

Futamura M, Yao J, Li X, Bergeron R, Tran JL, Zycband E, Woods J, Zhu Y, Shao Q, Maruki-Uchida H, Goto-Shimazaki H, Langdon RB, Erion MD, Eiki J, Zhou YP.

Diabetologia. 2012 Apr;55(4):1071-80. doi: 10.1007/s00125-011-2439-3. Epub 2012 Jan 11.

PMID:
22234649
14.

Insulin receptor-overexpressing β-cells ameliorate hyperglycemia in diabetic rats through Wnt signaling activation.

Kim MH, Hong SH, Lee MK.

PLoS One. 2013 Jul 9;8(7):e67802. doi: 10.1371/journal.pone.0067802. Print 2013.

15.

An α-quaternary chiral latam derivative, YH-304 as a novel broad-spectrum anticancer agent.

Hwang SJ, Park HG, Park Y, Lee HJ.

Int J Oncol. 2016 Dec;49(6):2480-2486. doi: 10.3892/ijo.2016.3726. Epub 2016 Oct 11.

PMID:
27748805
16.
17.

Atrial natriuretic peptide promotes pancreatic islet beta-cell growth and Akt/Foxo1a/cyclin D2 signaling.

You H, Laychock SG.

Endocrinology. 2009 Dec;150(12):5455-65. doi: 10.1210/en.2009-0468. Epub 2009 Oct 16.

PMID:
19837876
18.

Discovery of a novel phenylethyl benzamide glucokinase activator for the treatment of type 2 diabetes mellitus.

Park K, Lee BM, Kim YH, Han T, Yi W, Lee DH, Choi HH, Chong W, Lee CH.

Bioorg Med Chem Lett. 2013 Jan 15;23(2):537-42. doi: 10.1016/j.bmcl.2012.11.018. Epub 2012 Nov 16.

PMID:
23218712
19.

Impact of small-molecule glucokinase activator on glucose metabolism and beta-cell mass.

Nakamura A, Terauchi Y, Ohyama S, Kubota J, Shimazaki H, Nambu T, Takamoto I, Kubota N, Eiki J, Yoshioka N, Kadowaki T, Koike T.

Endocrinology. 2009 Mar;150(3):1147-54. doi: 10.1210/en.2008-1183. Epub 2008 Nov 13.

PMID:
19008318
20.

Differential modulation of Akt/glycogen synthase kinase-3beta pathway regulates apoptotic and cytoprotective signaling responses.

Nair VD, Olanow CW.

J Biol Chem. 2008 May 30;283(22):15469-78. doi: 10.1074/jbc.M707238200. Epub 2008 Apr 3.

Supplemental Content

Support Center